Veru, Inc. Hits New 52-Week Low at $2.34 Amid Ongoing Challenges

Veru, Inc., a microcap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 2.34 on November 19, 2025. This significant decline highlights ongoing challenges for the company, which has seen its stock price drop substantially from its 52-week high of USD 14.20.
Despite a notable one-year performance increase of 165.05%, Veru's recent trajectory has been concerning, particularly as it has underperformed the S&P 500, which recorded a 12.28% gain over the same period. The company's financial metrics reveal a challenging landscape, with a negative return on equity of -221.34% and a debt-to-equity ratio of -0.93, indicating financial strain.

Veru's operating profit has also seen a dramatic annual decline of -240.10% over the past five years, raising questions about its long-term growth prospects. The stock's performance has been further impacted by a negative EBITDA, reflecting ongoing profitability issues. As Veru navigates these financial hurdles, its current market cap stands at USD 57 million, underscoring its microcap status within the industry.